Connection

RADEK SKODA to Hematopoietic Stem Cells

This is a "connection" page, showing publications RADEK SKODA has written about Hematopoietic Stem Cells.
Connection Strength

4.288
  1. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
    View in: PubMed
    Score: 0.664
  2. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019 11 21; 134(21):1832-1846.
    View in: PubMed
    Score: 0.484
  3. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015 Mar 26; 125(13):2131-40.
    View in: PubMed
    Score: 0.346
  4. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
    View in: PubMed
    Score: 0.339
  5. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014 Apr; 99(4):e52-4.
    View in: PubMed
    Score: 0.324
  6. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood. 2011 Feb 10; 117(6):2075-6.
    View in: PubMed
    Score: 0.263
  7. Advances in the understanding and management of myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):2-4.
    View in: PubMed
    Score: 0.209
  8. Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
    View in: PubMed
    Score: 0.175
  9. IL-1? promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024 03 12; 8(5):1234-1249.
    View in: PubMed
    Score: 0.163
  10. Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells. Blood. 2004 Jun 15; 103(12):4511-3.
    View in: PubMed
    Score: 0.163
  11. Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches. Proc Natl Acad Sci U S A. 2021 10 05; 118(40).
    View in: PubMed
    Score: 0.138
  12. JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021 04 22; 137(16):2139-2151.
    View in: PubMed
    Score: 0.133
  13. Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion. Cell Stem Cell. 2021 03 04; 28(3):359-361.
    View in: PubMed
    Score: 0.132
  14. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020 04 30; 135(18):1548-1559.
    View in: PubMed
    Score: 0.125
  15. In vitro biomimetic engineering of a human hematopoietic niche with functional properties. Proc Natl Acad Sci U S A. 2018 06 19; 115(25):E5688-E5695.
    View in: PubMed
    Score: 0.109
  16. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014 Dec 04; 15(6):791-804.
    View in: PubMed
    Score: 0.086
  17. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
    View in: PubMed
    Score: 0.083
  18. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
    View in: PubMed
    Score: 0.082
  19. SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood. 2011 Jul 21; 118(3):723-35.
    View in: PubMed
    Score: 0.067
  20. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 2009 Feb 19; 113(8):1768-77.
    View in: PubMed
    Score: 0.056
  21. A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem. 2004 Aug 27; 279(35):36397-404.
    View in: PubMed
    Score: 0.042
  22. Chronic myeloproliferative disorders: molecular markers and pathogenesis. Hematol J. 2004; 5 Suppl 3:S122-5.
    View in: PubMed
    Score: 0.040
  23. Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. Nat Commun. 2023 10 12; 14(1):6414.
    View in: PubMed
    Score: 0.040
  24. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol. 1997 Apr; 11(4):393-9.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.